Almost exactly 4 years ago, Seres Therapeutics $MCRB experienced one of those soul-crunching failures that can raise big questions about a biotechs future. Out front in their pursuit of a gut punch to C. difficile infection (CDI), the Phase II test was a flat failure, and investors wiped out a billion dollars of equity value that never returned in the years that followed.<\/p>\n
Seres, though, pressed ahead, changing out CEOs a year ago bidding Merck vet Roger Pomerantz farewell from the C suite and pushing through a Phase III, hoping that amping up the dosage would make the key difference. And this morning, they unveiled a claim that they had aced the Phase III and positioned themselves for a run at a landmark FDA OK.<\/p>\n
Unlock this story instantly and join 86,800+ biopharma pros reading Endpoints daily and it's free. <\/p>\n
SUBSCRIBE SIGN IN <\/p>\n
<\/p>\n
Read more here: <\/p>\n
UPDATED: After a 4-year sojourn, struggling microbiome pioneer Seres claims a breakout PhIII comeback. And shares respond in frenzied spike -...<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" Almost exactly 4 years ago, Seres Therapeutics $MCRB experienced one of those soul-crunching failures that can raise big questions about a biotechs future. Out front in their pursuit of a gut punch to C Continue reading